Novo Undercuts Lilly’s Obesity Drug Price

Novo Undercuts Lilly’s Obesity Drug Price

Now Cheaper Than Car Payment

(ZH) – Just before the US cash session, Novo Nordisk A/S announced it will slash prices on Wegovy and Ozempic in a direct challenge to Eli Lilly’s obesity drug, aiming to regain market share. The announcement comes just weeks after President Trump finalized a deal with Novo and Lilly to reduce costs as part of the administration’s affordability push ahead of next year’s midterms.

Beginning immediately, introductory doses of Wegovy and Ozempic will cost just $199 per month for the first two months for cash-pay patients. After that, the price rises to $349 per month. This makes Novo’s obesity drugs approximately 30% cheaper than Lilly’s low-dose Zepbound and dramatically lower than the more than $1,000 per month many patients paid last year.

In the eyes of the consumer, $1,000 monthly payments for obesity drugs made little financial sense. However, now $349 per month could be viewed as “cheap” considering the average new car payment is $749 and the average used car payment is $529, according to the latest Experian data.

Novo pointed out that the price cut aligns with a recent agreement with the Trump administration to expand access to medicines for patients living with obesity and other chronic conditions like diabetes, while lowering prices in the direct-to-patient, self-pay channel for 2026, adding “Novo Nordisk is bringing these prices to consumers months in advance of that commitment.”

Earlier this month, Novo and Eli Lilly struck deals with the Trump administration to lower the prices of their blockbuster obesity drugs.

“I call it the fat drug … we’re offering it at drastic discounts,” Trump told reporters at the time.

Happening Now in the Oval Office with a behind the scenes view—President Trump: “Pharmaceutical companies @EliLillyandCo and @NovoNordisk have agreed to offer their most popular GLP-1 weight loss drug, I call it the fat drug…at drastic discounts…” LIVE @WhiteHouse @X! pic.twitter.com/3uJVTP96Ah

— Dan Scavino (@Scavino47) November 6, 2025

••••

The Liberty Beacon Project is now expanding at a near exponential rate, and for this we are grateful and excited! But we must also be practical. For 7 years we have not asked for any donations, and have built this project with our own funds as we grew. We are now experiencing ever increasing growing pains due to the large number of websites and projects we represent. So we have just installed donation buttons on our websites and ask that you consider this when you visit them. Nothing is too small. We thank you for all your support and your considerations … (TLB)

••••

Comment Policy: As a privately owned web site, we reserve the right to remove comments that contain spam, advertising, vulgarity, threats of violence, racism, or personal/abusive attacks on other users. This also applies to trolling, the use of more than one alias, or just intentional mischief. Enforcement of this policy is at the discretion of this websites administrators. Repeat offenders may be blocked or permanently banned without prior warning.

••••

Disclaimer: TLB websites contain copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of “fair use” in an effort to advance a better understanding of political, health, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than “fair use” you must request permission from the copyright owner.

••••

Disclaimer: The information and opinions shared are for informational purposes only including, but not limited to, text, graphics, images and other material are not intended as medical advice or instruction. Nothing mentioned is intended to be a substitute for professional medical advice, diagnosis or treatment.